1. Home
  2. HQY vs BPMC Comparison

HQY vs BPMC Comparison

Compare HQY & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HQY
  • BPMC
  • Stock Information
  • Founded
  • HQY 2002
  • BPMC 2008
  • Country
  • HQY United States
  • BPMC United States
  • Employees
  • HQY N/A
  • BPMC N/A
  • Industry
  • HQY Business Services
  • BPMC Biotechnology: Pharmaceutical Preparations
  • Sector
  • HQY Consumer Discretionary
  • BPMC Health Care
  • Exchange
  • HQY Nasdaq
  • BPMC Nasdaq
  • Market Cap
  • HQY 8.7B
  • BPMC 8.3B
  • IPO Year
  • HQY 2014
  • BPMC 2015
  • Fundamental
  • Price
  • HQY $96.18
  • BPMC $129.35
  • Analyst Decision
  • HQY Strong Buy
  • BPMC Buy
  • Analyst Count
  • HQY 12
  • BPMC 20
  • Target Price
  • HQY $117.42
  • BPMC $127.82
  • AVG Volume (30 Days)
  • HQY 1.0M
  • BPMC 3.3M
  • Earning Date
  • HQY 09-02-2025
  • BPMC 07-31-2025
  • Dividend Yield
  • HQY N/A
  • BPMC N/A
  • EPS Growth
  • HQY 48.80
  • BPMC N/A
  • EPS
  • HQY 1.37
  • BPMC N/A
  • Revenue
  • HQY $1,243,021,000.00
  • BPMC $562,121,000.00
  • Revenue This Year
  • HQY $9.60
  • BPMC $44.46
  • Revenue Next Year
  • HQY $8.97
  • BPMC $32.78
  • P/E Ratio
  • HQY $70.51
  • BPMC N/A
  • Revenue Growth
  • HQY 19.21
  • BPMC 99.19
  • 52 Week Low
  • HQY $65.01
  • BPMC $73.04
  • 52 Week High
  • HQY $116.65
  • BPMC $129.49
  • Technical
  • Relative Strength Index (RSI)
  • HQY 39.56
  • BPMC 76.77
  • Support Level
  • HQY $93.65
  • BPMC $129.00
  • Resistance Level
  • HQY $104.93
  • BPMC $129.47
  • Average True Range (ATR)
  • HQY 2.71
  • BPMC 0.25
  • MACD
  • HQY -1.05
  • BPMC -0.88
  • Stochastic Oscillator
  • HQY 19.54
  • BPMC 90.21

About HQY HealthEquity Inc.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Share on Social Networks: